Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000152245 | SCV000201052 | uncertain significance | not specified | 2014-07-03 | criteria provided, single submitter | clinical testing | The Gly19872Ser variant in TTN has not been previously reported in individuals w ith cardiomyopathy or in large population studies. Computational prediction tool s and conservation analysis suggest that this variant may not impact the protein , though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of the GLy19872Ser variant is uncertain. |
Ambry Genetics | RCV002354351 | SCV002621128 | uncertain significance | Cardiovascular phenotype | 2019-07-11 | criteria provided, single submitter | clinical testing | The p.G13375S variant (also known as c.40123G>A), located in coding exon 145 of the TTN gene, results from a G to A substitution at nucleotide position 40123. The glycine at codon 13375 is replaced by serine, an amino acid with similar properties. This variant (reported as p.G22440S, c.67318G>A) has been detected in a hypertrophic cardiomyopathy cohort; however, details were limited (Marian AJ et al. Circ. Res., 2018 Apr;122:1109-1118). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002498711 | SCV002806757 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J; Tibial muscular dystrophy; Myopathy, myofibrillar, 9, with early respiratory failure; Early-onset myopathy with fatal cardiomyopathy; Hypertrophic cardiomyopathy 9 | 2021-10-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003147354 | SCV003834884 | uncertain significance | Tibial muscular dystrophy | 2021-02-05 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003147352 | SCV003834887 | uncertain significance | Hypertrophic cardiomyopathy 9 | 2021-02-05 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003147356 | SCV003835009 | uncertain significance | Myopathy, myofibrillar, 9, with early respiratory failure | 2021-02-05 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003147353 | SCV003835018 | uncertain significance | Dilated cardiomyopathy 1G | 2021-02-05 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003147357 | SCV003835150 | uncertain significance | Early-onset myopathy with fatal cardiomyopathy | 2021-02-05 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003147355 | SCV003835928 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2J | 2021-02-05 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003480066 | SCV004225827 | uncertain significance | not provided | 2022-05-17 | criteria provided, single submitter | clinical testing | BP4, PM2 |